Clinical Effect of Changyanqing Mixture Combined with Mesalazine Enteric-coated Tablets for Maintenance Treatment of Ulcerative Colitis in Remission Period
10.13422/j.cnki.syfjx.20202324
- VernacularTitle:肠炎清合剂联合美沙拉嗪肠溶片维持治疗缓解期溃疡性结肠炎的临床疗效
- Author:
Long-ling CONG
1
;
Jia-yin YAO
2
;
Yu-jin WU
1
;
Yong-hui LYU
1
Author Information
1. Affiliated Traditional Chinese Medicine Hospital of Guangzhou Medical University， Guangzhou 510130， China
2. The Sixth Affiliated Hospital， Sun Yat Sen University， Guangzhou 510011， China
- Publication Type:Research Article
- Keywords:
ulcerative colitis;
remission period;
maintenance treatment;
Changyanqing mixture;
mesalazine enteric-coated tablets;
faecal calprotectin;
recurrence
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2021;27(3):99-104
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This study aims to evaluate the clinical effect of Changyanqing mixture combined with mesalazine enteric-coated tablets in the maintenance treatment of ulcerative colitis（UC） in remission period. Method:The 140 patients with UC in remission period were randomly divided into control group （70 cases） and observation group （70 cases）. The 61 patients in control group completed the therapy （6 cases lost or lost to follow-up and 3 were eliminated）， 63 patients in observation group completed the therapy （5 cases lost or lost to follow-up and 2 were eliminated）. Both groups′ patients got treatment of lifestyle adjustment， and they also took mesalazine enteric-coated tablets orally， 0.5 g/time， 3 times/day. Patients in observation group took Changyanqing mixture orally for a month in the morning and evening every day， 150 mL/time， and then changed to 150 mL/time， 1 time/day， for 3 consecutive months， finally changed to once every other day for 8 months. Patients in control group took simulated medicine of Changyanqing mixture orally in the same way as observation group. The treatment was continued for 12 months. When UC recurred during the treatment， patients took mesalazine enteric-coated tablets orally at 1 g/time， 3 times/day until remission， when the above intervention plan was continued to be adopted. The recurrence rate， first recurrence time within 12 months （duration from remission to Mayo≥3） and the degree of disease activity at recurrence were recorded. Scores of traditional Chinese medicine（TCM）syndrome and inflammatory bowel disease questionnaire （IBDQ） were evaluated once every 2 months. Before treatment， and at the 6th and 12th month after treatment， colonoscopy and mucosal histology were performed once， enteroscopic mucosal scores， Geboes index of mucosal histology were evaluated， and fecal calprotectin（FC） levels were detected. Also， safety evaluation was conducted. Result:During 12 months， the recurrence rate in observation group was 20.63% （13/63）， lower than 39.34% （24/61） in control group（P<0.05）， the frequency of recurrence and the first recurrence duration in observation group were all less than those in control group（P<0.01）. All these meant the disease activity of patients in observation group was lighter than that in control group （χ2
![]()
![]()
=5.947， P<0.05）. After repeated measurements of variance analysis， scores of TCM syndrome， enteroscopic mucosal scores， Geboes index and FC levels in two groups gradually increased（P<0.05）， and scores of IBDQ gradually decreased （P<0.05） during the 12-month period. At the second， fourth， sixth， eighth， tenth and twelfth month， scores of TCM syndromes in observation group were lower than those in control group （P<0.01）， and scores of IBDQ were higher than those in control group （P<0.01）. At the sixth and twelfth month after treatment， intestinal endoscopic mucosal scores， Geboes index and FC levels in observation group were all lower than those in control group （P<0.01）. And there were no adverse reactions related to Changyanqing mixture. Conclusion:Changyanqing mixture combined with mesalazine enteric-coated tablets in the maintenance treatment of patients with UC in remission can control the FC level， further reduce the recurrence rate， delay the recrudescence-time， reduce the frequency of UC and the disease activity， maintain the good remission state of UC， stabilize the quality of life of patients， and ensure the safety of clinical use.
